INSM - INSMED Inc

143.57
-6.310   -4.395%

Share volume: 2,267,930
Last Updated: 03-05-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.31%

PREVIOUS CLOSE
CHG
CHG%
$149.88
-6.31
-0.04%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
9%
Profitability 0%
Dept financing 15%
Liquidity 75%
Performance 0%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-1.88%
1 Month
-4.20%
3 Months
-26.95%
6 Months
-2.12%
1 Year
91.38%
2 Year
412.93%
Key data
Stock price
$143.57
P/E Ratio 
0.00
DAY RANGE
$142.04 - $148.07
EPS 
-$6.42
52 WEEK RANGE
$60.40 - $212.75
52 WEEK CHANGE
$91.71
MARKET CAP 
37.118 B
YIELD 
N/A
SHARES OUTSTANDING 
215.552 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
08-07-2025
BETA 
1.87
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$2,352,808
AVERAGE 30 VOLUME 
$2,425,606
Company detail
CEO: William H. Lewis
Region: US
Website: insmed.com
Employees: 740
IPO year: 2000
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1.

Recent news